The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

2018 KHRS Guidelines for Stroke Prevention Therapy in Korean Patients with Nonvalvular Atrial Fibrillation

2018 대한부정맥학회 비판막성 심방세동 환자의 뇌졸중 예방 지침

  • Lee, Jung Myung (Division of Cardiology, Kyung Hee University Hospital) ;
  • Joung, Boyoung (Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Cha, Myung-Jin (Department of Internal Medicine, Seoul National University Hospital) ;
  • Lee, Ji Hyun (Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Lim, Woo Hyun (Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine) ;
  • Kim, Tae-Hoon (Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Shin, Seung Yong (Department of Cardiology, Chung-Ang University Hospital) ;
  • Uhm, Jae-Sun (Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Lim, Hong Euy (Cardiovascular Center, Korea University Guro Hospital) ;
  • Kim, Jin-Bae (Division of Cardiology, Kyung Hee University Hospital) ;
  • Kim, Jun Soo (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 이정명 (경희대학교병원 순환기내과) ;
  • 정보영 (연세대학교 세브란스병원 순환기내과) ;
  • 차명진 (서울대학교병원 순환기내과) ;
  • 이지현 (서울대학교 분당병원 순환기내과) ;
  • 임우현 (서울대학교 보라매병원 순환기내과) ;
  • 김태훈 (연세대학교 세브란스병원 순환기내과) ;
  • 신승용 (중앙대학교병원 순환기내과) ;
  • 엄재선 (연세대학교 세브란스병원 순환기내과) ;
  • 임홍의 (고려대학교 구로병원 순환기내과) ;
  • 김진배 (경희대학교병원 순환기내과) ;
  • 김준수 (성균관대학교 삼성서울병원 순환기내과)
  • Published : 2018.04.01
⟨ Previous Next ⟩

Abstract

Atrial fibrillation (AF) is the most common cardiac abnormality associated with ischemic stroke. Anticoagulant therapy plays an important role in the prevention of stroke associated with AF. Risk stratification and selection of oral anticoagulants in patients with AF are usually performed according to international guidelines from Europe or the United States of America. However, pivotal trials enrolled only a small number of Asian subjects, limiting the application of international guidelines to Korean patients with AF. The Korean Heart Rhythm Society organized a Korean AF Management Guideline Committee and analyzed all available studies regarding the management of AF, including studies on Korean patients. Expert consensus or guidelines for the optimal management of Korean patients with AF were achieved after a systematic review with intensive discussion. This article provides general principles for appropriate risk stratification and selection of anticoagulation therapy in Korean patients with AF.

Keywords

References

  1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest 2010;137:263-272. https://doi.org/10.1378/chest.09-1584
  2. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-1420. https://doi.org/10.1093/europace/euq350
  3. Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, John Camm A. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013;34:1471-1474. https://doi.org/10.1093/eurheartj/ehs446
  4. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA 2015;313:1950-1962. https://doi.org/10.1001/jama.2015.4369
  5. Mason PK, Lake DE, DiMarco JP, et al. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med 2012;125: 603.e1-e6. https://doi.org/10.1016/j.amjmed.2011.09.030
  6. Kim TH, Yang PS, Kim D, et al. CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean nationwide cohort study. Stroke 2017;48:2984-2990. https://doi.org/10.1161/STROKEAHA.117.018551
  7. Kang SH, Choi EK, Han KD, et al. Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants-Korean nationwide population-based Study. Circ J 2017;81:1158-1164. https://doi.org/10.1253/circj.CJ-16-1267
  8. Kim TH, Yang PS, Uhm JS, et al. CHA2DS2-VASc score (congestive heart failure, hypertension, age ${\geq}75$ [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65-74, female) for stroke in asian patients with atrial fibrillation: a Korean nationwide sample cohort study. Stroke 2017;48:1524-1530. https://doi.org/10.1161/STROKEAHA.117.016926
  9. Lee SR, Choi EK, Han KD, Cha MJ, Oh S. Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. Int J Cardiol 2017;236:226-231. https://doi.org/10.1016/j.ijcard.2017.02.039
  10. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124. https://doi.org/10.1136/bmj.d124
  11. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015;65:635-642. https://doi.org/10.1016/j.jacc.2014.11.046
  12. Lip GY, Skjo̸th F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:1385-1394. https://doi.org/10.1016/j.jacc.2015.01.044
  13. Fauchier L, Lecoq C, Clementy N, et al. Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: The Loire Valley atrial fibrillation project. Chest 2016;149:960-968. https://doi.org/10.1378/chest.15-1622
  14. Joundi RA, Cipriano LE, Sposato LA, Saposnik G; Stroke Outcomes Research Working Group. Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1: systematic review and meta-analysis. Stroke 2016;47:1364-1367. https://doi.org/10.1161/STROKEAHA.115.012609
  15. Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015;65:225-232. https://doi.org/10.1016/j.jacc.2014.10.052
  16. Allan V, Banerjee A, Shah AD, et al. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. Heart 2017;103:210-218. https://doi.org/10.1136/heartjnl-2016-309910
  17. Lip GY, Skjo̸th F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015;114:826-834. https://doi.org/10.1160/TH15-07-0565
  18. Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 2012;10:1745-1751. https://doi.org/10.1111/j.1538-7836.2012.04853.x
  19. Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM 2014;107:955-967. https://doi.org/10.1093/qjmed/hcu054
  20. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011;4:14-21. https://doi.org/10.1161/CIRCOUTCOMES.110.958108
  21. Overvad TF, Nielsen PB, Lip GY. Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score. Eur Heart J Cardiovasc Pharmacother 2017;3:37-41. https://doi.org/10.1093/ehjcvp/pvw022
  22. Hijazi Z, Lindback J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarkerbased risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016;37:1582-1590. https://doi.org/10.1093/eurheartj/ehw054
  23. Lee JM, Kim JB, Uhm JS, Pak HN, Lee MH, Joung B. Additional value of left atrial appendage geometry and hemodynamics when considering anticoagulation strategy in patients with atrial fibrillation with low $CHA_{2}DS_{2}$-VASc scores. Heart Rhythm 2017;14:1297-1301. https://doi.org/10.1016/j.hrthm.2017.05.034
  24. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J 1964;1:1209-1212. https://doi.org/10.1136/bmj.1.5392.1209
  25. Olesen KH. The natural history of 271 patients with mitral stenosis under medical treatment. Br Heart J 1962;24:349-357. https://doi.org/10.1136/hrt.24.3.349
  26. Perez-Gomez F, Alegria E, Berjon J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004;44:1557-1566. https://doi.org/10.1016/j.jacc.2004.05.084
  27. Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis without surgery: ten- and twenty-year perspectives. Ann Intern Med 1960;52:741-749. https://doi.org/10.7326/0003-4819-52-4-741
  28. Wilson JK, Greenwood WF. The natural history of mitral stenosis. Can Med Assoc J 1954;71:323-331.
  29. Cannegieter SC, van der Meer FJ, Briet E, Rosendaal FR. Warfarin and aspirin after heart-valve replacement. N Engl J Med 1994;330:507-508; author reply 508-509.
  30. Chiang CW, Lo SK, Ko YS, Cheng NJ, Lin PJ, Chang CH. Predictors of systemic embolism in patients with mitral stenosis. A prospective study. Ann Intern Med 1998;128:885-889. https://doi.org/10.7326/0003-4819-128-11-199806010-00001
  31. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-1214. https://doi.org/10.1056/NEJMoa1300615
  32. Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;35:3377-3385. https://doi.org/10.1093/eurheartj/ehu305
  33. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation 2015;132:624-632. https://doi.org/10.1161/CIRCULATIONAHA.114.014807
  34. Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 2017;135:1273-1275. https://doi.org/10.1161/CIRCULATIONAHA.116.026714
  35. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401. https://doi.org/10.1016/j.jacc.2011.03.031
  36. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-719. https://doi.org/10.1016/j.ahj.2005.04.017
  37. Hijazi Z, Oldgren J, Lindback J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016;387:2302-2311. https://doi.org/10.1016/S0140-6736(16)00741-8
  38. O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015;36:3258-3264.
  39. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey. Chest 2010;138:1093-1100. https://doi.org/10.1378/chest.10-0134
  40. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151. https://doi.org/10.1056/NEJMoa0905561
  41. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104. https://doi.org/10.1056/NEJMoa1310907
  42. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992. https://doi.org/10.1056/NEJMoa1107039
  43. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891. https://doi.org/10.1056/NEJMoa1009638
  44. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-1876. https://doi.org/10.1056/NEJMc1007378
  45. Sjogren V, Grzymala-Lubanski B, Renlund H, et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 2015;113:1370-1377. https://doi.org/10.1160/TH14-10-0859
  46. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-2037. https://doi.org/10.1161/CIRCULATIONAHA.107.750000
  47. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84-91. https://doi.org/10.1161/CIRCOUTCOMES.108.796185
  48. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009;124:37-41. https://doi.org/10.1016/j.thromres.2008.09.016
  49. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106:968-977. https://doi.org/10.1160/TH11-05-0353
  50. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). position paper of the ESC Working Group on thrombosis--task force on anticoagulants in heart disease. Thromb Haemost 2013;110:1087-1107. https://doi.org/10.1160/TH13-06-0443
  51. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-2789. https://doi.org/10.1093/eurheartj/ehr113
  52. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867. https://doi.org/10.7326/0003-4819-146-12-200706190-00007
  53. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-983. https://doi.org/10.1016/S0140-6736(10)61194-4
  54. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-749. https://doi.org/10.1160/TH11-05-0364
  55. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2013;127:634-640. https://doi.org/10.1161/CIRCULATIONAHA.112.115386
  56. Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 2014;16:631-638. https://doi.org/10.1093/europace/eut333
  57. Raunso J, Selmer C, Olesen JB, et al. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J 2012;33:1886-1892. https://doi.org/10.1093/eurheartj/ehr454
  58. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-164. https://doi.org/10.1161/CIRCULATIONAHA.114.012061
  59. Choi WS, Kim JH, Jang SY, et al. Optimal international normalized ratio for warfarin therapy in elderly Korean patients with non-valvular atrial fibrillation. Int J Arrhythm 2016;17:167-173. https://doi.org/10.18501/arrhythmia.2016.029
  60. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013;144:1555-1563. https://doi.org/10.1378/chest.13-0054
  61. Gallego P, Roldan V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014;127:1083-1088. https://doi.org/10.1016/j.amjmed.2014.05.023
  62. Lip GYH, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT2R2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014;146:719-726. https://doi.org/10.1378/chest.13-2976
  63. Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016;353:i3189.
  64. Cha MJ, Choi EK, Han KD, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation. Stroke 2017;48:3040-3048. https://doi.org/10.1161/STROKEAHA.117.018773
  65. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364: 806-817. https://doi.org/10.1056/NEJMoa1007432
  66. Olesen JB, So̸rensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 2015;17:187-193. https://doi.org/10.1093/europace/euu225
  67. Choi EJ, Lee IH, Je NK. Inadequate stroke prevention in Korean atrial fibrillation patients in the post-warfarin era. Int J Cardiol 2016;220:647-652. https://doi.org/10.1016/j.ijcard.2016.06.177
  68. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:2141-2147. https://doi.org/10.1016/j.jacc.2014.02.549
  69. Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke 2018;49:98-106. https://doi.org/10.1161/STROKEAHA.117.018395
  70. Joung B. Real-world data and recommended dosage of non-vitamin K oral anticoagulants for Korean patients. Korean Circ J 2017;47:833-841. https://doi.org/10.4070/kcj.2017.0158
  71. Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol 2016;68:1389-1401. https://doi.org/10.1016/j.jacc.2016.06.062
  72. Pollack CV, Jr., Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal-full cohort analysis. N Engl J Med 2017;377:431-441. https://doi.org/10.1056/NEJMoa1707278
  73. Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385:2288-2295. https://doi.org/10.1016/S0140-6736(14)61943-7
  74. Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the dresden NOAC registry. Blood 2014;124:955-962. https://doi.org/10.1182/blood-2014-03-563577
  75. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145-1153. https://doi.org/10.1093/eurheartj/ehv466
  76. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962. https://doi.org/10.1016/S0140-6736(13)62343-0
  77. Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2014;3:e000521. https://doi.org/10.1161/JAHA.113.000521
  78. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-2394. https://doi.org/10.1093/eurheartj/ehr342
  79. Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012;21:429-435. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.05.007
  80. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821-2830. https://doi.org/10.1093/eurheartj/ehs274
  81. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis. Circulation 2014;129:961-970. https://doi.org/10.1161/CIRCULATIONAHA.113.003628
  82. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011;6:2599-2604. https://doi.org/10.2215/CJN.02400311
  83. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish atrial fibrillation cohort study. Eur Heart J 2015;36:297-306. https://doi.org/10.1093/eurheartj/ehu139
  84. Jun M, James MT, Manns BJ, et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ 2015;350:h246. https://doi.org/10.1136/bmj.h246
  85. Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol 2016;117:69-75. https://doi.org/10.1016/j.amjcard.2015.09.046
  86. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507. https://doi.org/10.1093/europace/euv309
  87. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012;27:3816-3822. https://doi.org/10.1093/ndt/gfs416
  88. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-1106. https://doi.org/10.1038/ki.2009.477
  89. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-2233. https://doi.org/10.1681/ASN.2009030319
  90. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011;6:2662-2668. https://doi.org/10.2215/CJN.04550511
  91. Schwartzenberg S, Lev EI, Sagie A, Korzets A, Kornowski R. The quandary of oral anticoagulation in patients with atrial fibrillation and chronic kidney disease. Am J Cardiol 2016;117:477-482. https://doi.org/10.1016/j.amjcard.2015.10.065
  92. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196-1203. https://doi.org/10.1161/CIRCULATIONAHA.113.004777
  93. Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014;64:2471-2482. https://doi.org/10.1016/j.jacc.2014.09.051
  94. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-1912. https://doi.org/10.1016/S0140-6736(06)68845-4
  95. ACTIVE Investigators, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078. https://doi.org/10.1056/NEJMoa0901301
  96. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. https://doi.org/10.1016/S0140-6736(07)61233-1
  97. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009;40:1410-1416. https://doi.org/10.1161/STROKEAHA.108.526988
  98. Budera P, Straka Z, Osmancik P, et al. Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. Eur Heart J 2012;33:2644-2652. https://doi.org/10.1093/eurheartj/ehs290
  99. Healey JS, Crystal E, Lamy A, et al. Left atrial appendage occlusion study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005;150:288-293. https://doi.org/10.1016/j.ahj.2004.09.054
  100. Holmes DR, Jr., Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:1-12. https://doi.org/10.1016/j.jacc.2014.04.029
  101. Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 2015;65:2614-2623. https://doi.org/10.1016/j.jacc.2015.04.025
  102. Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. Circulation 2013;127:720-729. https://doi.org/10.1161/CIRCULATIONAHA.112.114389
  103. Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. Eur J Cardiothorac Surg 2015;47:847-854. https://doi.org/10.1093/ejcts/ezu291
  104. Boersma LV, Castella M, van Boven W, et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation 2012;125:23-30. https://doi.org/10.1161/CIRCULATIONAHA.111.074047
  105. Bajaj NS, Parashar A, Agarwal S, et al. Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies. JACC Cardiovasc Interv 2014;7:296-304. https://doi.org/10.1016/j.jcin.2013.11.010
  106. Lewalter T, Kanagaratnam P, Schmidt B, et al. Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion. Europace 2014;16:626-630. https://doi.org/10.1093/europace/euu069
  107. Meier B, Blaauw Y, Khattab AA, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace 2014;16:1397-1416. https://doi.org/10.1093/europace/euu174
  108. Kim JS, Lee H, Suh Y, et al. Left atrial appendage occlusion in non-valvular atrial fibrillation in a Korean multi-center registry. Circ J 2016;80:1123-1130. https://doi.org/10.1253/circj.CJ-15-1134
  109. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-542. https://doi.org/10.1016/S0140-6736(09)61343-X
  110. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014;312:1988-1998. https://doi.org/10.1001/jama.2014.15192
  111. Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER cardiac plug. EuroIntervention 2016;11:1188-1194. https://doi.org/10.4244/EIJY14M10_12
  112. Badheka AO, Chothani A, Mehta K, et al. Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States: influence of hospital volume. Circ Arrhythm Electrophysiol 2015;8:42-48. https://doi.org/10.1161/CIRCEP.114.001413
  113. Pison L, Potpara TS, Chen J, et al. Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. Europace 2015;17:642-646. https://doi.org/10.1093/europace/euv069
  114. Price MJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol 2014;64:565-572. https://doi.org/10.1016/j.jacc.2014.03.057
  115. Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 2016;37:2465-2474. https://doi.org/10.1093/eurheartj/ehv730
  116. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015;313:824-836. https://doi.org/10.1001/jama.2015.0846
  117. Casu G, Gulizia MM, Molon G, et al. ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training. Eur Heart J Suppl 2017;19(Suppl D):D333-D353. https://doi.org/10.1093/eurheartj/sux008
  118. Katz ES, Tsiamtsiouris T, Applebaum RM, Schwartzbard A, Tunick PA, Kronzon I. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study. J Am Coll Cardiol 2000;36:468-471. https://doi.org/10.1016/S0735-1097(00)00765-8
  119. Whitlock R, Healey J, Vincent J, et al. Rationale and design of the left atrial appendage occlusion study (LAAOS) III. Ann Cardiothorac Surg 2014;3:45-54.
  120. Aryana A, Singh SK, Singh SM, et al. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. Heart Rhythm 2015;12:1431-1437. https://doi.org/10.1016/j.hrthm.2015.03.028
  121. Xian Y, Liang L, Smith EE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012;307:2600-2608.
  122. Mazya MV, Lees KR, Markus R, et al. Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol 2013;74:266-274. https://doi.org/10.1016/j.neuroimage.2013.01.042
  123. Park YA, Uhm JS, Pak HN, Lee MH, Joung B. Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. Heart Rhythm 2016;13:1794-1802. https://doi.org/10.1016/j.hrthm.2016.05.016
  124. Felmeden DC, Lip GY. Antithrombotic therapy in hypertension: a cochrane systematic review. J Hum Hypertens 2005;19:185-196. https://doi.org/10.1038/sj.jhh.1001807
  125. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-2372. https://doi.org/10.1161/CIRCULATIONAHA.110.004747
  126. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350:h1585. https://doi.org/10.1136/bmj.h1585
  127. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857. https://doi.org/10.1136/bmj.h1857
  128. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 2015;132:194-204. https://doi.org/10.1161/CIRCULATIONAHA.114.013267
  129. Palareti G, Cosmi B. Bleeding with anticoagulation therapy-who is at risk, and how best to identify such patients. Thromb Haemost 2009;102:268-278. https://doi.org/10.1160/TH08-11-0730
  130. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823-833. https://doi.org/10.1056/NEJMoa1501035
  131. Kim TH, Kim JY, Mun HS, et al. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis. J Thromb Haemost 2015;13:182-190. https://doi.org/10.1111/jth.12810
  132. Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace 2013;15:787-797. https://doi.org/10.1093/europace/eut001
  133. Hughes M, Lip GY; Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007;100:599-607. https://doi.org/10.1093/qjmed/hcm076
  134. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-2219. https://doi.org/10.1093/eurheartj/eht151
  135. Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014;63:891-900. https://doi.org/10.1016/j.jacc.2013.11.013
  136. Nielsen PB, Skjo̸th F, So̸gaard M, Kjældgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017;356:j510.
  137. Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol 2015;104:418-429. https://doi.org/10.1007/s00392-014-0797-9
  138. Lee SJ, Shin DH, Hwang HJ, et al. Bleeding risk and major adverse events in patients with previous ulcer on oral anticoagulation therapy. Am J Cardiol 2012;110:373-377. https://doi.org/10.1016/j.amjcard.2012.03.036
  139. Lee SJ, Sung JH, Kim JB, et al. The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding: Long-term results from a multicenter study. Medicine (Baltimore) 2016;95:e5467. https://doi.org/10.1097/MD.0000000000005467
  140. Bjorck F, Renlund H, Lip GY, Wester P, Svensson PJ, Sjalander A. Outcomes in a warfarin-treated population with atrial fibrillation. JAMA Cardiol 2016;1:172-180. https://doi.org/10.1001/jamacardio.2016.0199
  141. Oh S, Goto S, Accetta G, et al. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry. Int J Cardiol 2016;223:543-547. https://doi.org/10.1016/j.ijcard.2016.08.236
  142. Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother 2009;7: 159-166. https://doi.org/10.1016/j.amjopharm.2009.06.002
  143. Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley atrial fibrillation project. Am J Med 2014;127:972-978. https://doi.org/10.1016/j.amjmed.2014.05.035
  144. van Schie RM, Wadelius MI, Kamali F, et al. Genotypeguided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009;10:1687-1695. https://doi.org/10.2217/pgs.09.125
  145. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-764. https://doi.org/10.1056/NEJMoa0809329
  146. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358:999-1008. https://doi.org/10.1056/NEJMoa0708078
  147. Tang T, Liu J, Zuo K, et al. Genotype-guided dosing of coumarin anticoagulants: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 2015;20:387-394. https://doi.org/10.1177/1074248414565666
  148. Niessner A, Tamargo J, Morais J, et al. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2017;38:1710-1716.
  149. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64:1128-1139. https://doi.org/10.1016/j.jacc.2014.05.065
  150. Hanley J. Warfarin reversal. J Clin Pathol 2004;57:1132-1139. https://doi.org/10.1136/jcp.2003.008904
  151. Parry-Jones AR, Di Napoli M, Goldstein JN, et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol 2015;78:54-62. https://doi.org/10.1002/ana.24416
  152. Goldstein JN, Refaai MA, Milling TJ, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015;385:2077-2087. https://doi.org/10.1016/S0140-6736(14)61685-8
  153. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-520. https://doi.org/10.1056/NEJMoa1502000
  154. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413-2424. https://doi.org/10.1056/NEJMoa1510991
  155. Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol 2015;35:1736-1745. https://doi.org/10.1161/ATVBAHA.114.303402
  156. Staerk L, Fosbo̸l EL, Gadsbo̸ll K, et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011-2015 in Denmark. Sci Rep 2016;6:31477. https://doi.org/10.1038/srep31477
  157. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-1115. https://doi.org/10.1016/S0140-6736(12)62177-1
  158. Braun OO, Bico B, Chaudhry U, et al. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thromb Res 2015;135:26-30. https://doi.org/10.1016/j.thromres.2014.10.016
  159. Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013;61:2060-2066. https://doi.org/10.1016/j.jacc.2013.02.036
  160. Oldgren J, Wallentin L, Alexander JH, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013;34:1670-1680. https://doi.org/10.1093/eurheartj/eht049
  161. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513-1524. https://doi.org/10.1056/NEJMoa1708454
  162. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423-2434. https://doi.org/10.1056/NEJMoa1611594
  163. Vranckx P, Lewalter T, Valgimigli M, et al. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful Percutaneous Coronary Intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI Trial. Am Heart J 2018;196:105-112. https://doi.org/10.1016/j.ahj.2017.10.009

Cited by

  1. Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients vol.48, pp.8, 2018, https://doi.org/10.4070/kcj.2018.0190
  2. 2018 KHRS Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Atrial Fibrillation: How to Initiate and Organize the Follow-up vol.94, pp.1, 2018, https://doi.org/10.3904/kjm.2019.94.1.17
  3. Guideline of atrial fibrillation management vol.62, pp.5, 2019, https://doi.org/10.5124/jkma.2019.62.5.265
  4. Korean Heart Rhythm Society 2019 Practical Guidelines on Antithrombotic Therapy for AF Patients Undergoing Percutaneous Coronary Intervention or Structural Heart Disease Intervention vol.94, pp.4, 2019, https://doi.org/10.3904/kjm.2019.94.4.330
  5. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients vol.41, pp.6, 2019, https://doi.org/10.1007/s11096-019-00901-8